By Ilan Zipkin
& Steve Usdin
Staff Writers

Adverse events reported with the first approved COX-2 inhibitor last week failed to garner special attention of an FDA panel convened to review a second version of the molecule. But the agency and its advisors are raising concerns about potential difficulties created by dosing that routinely exceeds that prescribed by the label.